Changes in bone mineral density during 5 years of adjuvant treatment in premenopausal breast cancer patients

Minsung Kim, Hanna Kim, Sei Hyun Ahn, Vafa Tabatabaie, Sung Wook Choi, Guiyun Sohn, Sae Byul Lee, Beom Seok Ko, Il Yong Chung, Jisun Kim, Jong Won Lee, Byung Ho Son, Hee Jeong Kim

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Purpose: Adjuvant treatment for breast cancer in postmenopausal women is a risk factor for bone loss. However, the association between bone mineral density (BMD) changes in premenopausal breast cancer patients and various adjuvant treatment regimens is not well characterized. In this study, we evaluated the changes in BMD according to adjuvant treatment in premenopausal women with breast cancer. Methods: Between 2006 and 2010, BMD data of 910 premenopausal women with breast cancer before operation and 1, 2, 3.5, and 5 years post-operation were retrospectively analyzed. The patients were divided according to the type of treatment: observation (O), tamoxifen (T), chemotherapy (C), C followed by T (C → T), and gonadotropin-releasing hormone (GnRH) agonist with T (G + T). Results: After 5 years of follow-up, BMD changes were similar between the T and O groups (all p > 0.05). Within 1 year of treatment, the C group showed the most significant BMD loss. The C → T and G + T groups showed more significant BMD loss in the lumbar spine and femur than the O and T groups (both p < 0.001, both). After 1 year of treatment, BMD loss in the lumbar spine was significantly greater in the C → T and G + T groups than in the T group; this tendency was maintained for 5 years of treatment (all p < 0.005). Conclusion: Premenopausal women who received adjuvant treatment which induced menopause showed significant bone loss which lasted for 5 years. Although no significant difference was observed between the O and T groups, tamoxifen treatment during chemotherapy or GnRH agonist treatment might prevent bone loss.

Original languageEnglish (US)
Pages (from-to)657-663
Number of pages7
JournalBreast Cancer Research and Treatment
Issue number3
StatePublished - Apr 1 2020


  • Adjuvant treatment
  • Bone mineral density
  • Chemotherapy
  • Ovarian suppression
  • Premenopausal

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Changes in bone mineral density during 5 years of adjuvant treatment in premenopausal breast cancer patients'. Together they form a unique fingerprint.

Cite this